로딩 중…
StockDiggingStockDigging

Attovia Therapeutics Inc. Common Stock

ATTO· NASDAQ
$20.80+2.92%
2026-08-21

Financials

Valuation Metrics

Attovia Therapeutics Inc. Common Stock's Market Cap is $801M. Ranked #2545 of 3,119 in US market (top 82%), #1061 of 1,458 on NASDAQ (top 73%) by Market Cap.

Investment Metrics(as of 2026-08-23)

MetricValue
Size
Market Cap$801M
Revenue$1M
Net Income$-61M
Total Assets$166M
Net Assets$151M
Employees44
Value
P/B5.94x
P/S662.97x
FCF Yield-7.68%
Profitability
ROE-40.21%
ROA-36.55%
Op. Margin-4974.74%
Financial Health
Debt Ratio10.02%
Total Debt$5M
FCF$-62M
Cash$40M
Current Ratio14.20x
Trading
Volume361,555 shares
Trading Value$7M
Per Share
EPS$-1.41
BPS$3.50

Company Info

CEO Tao Fu
Employees 44
HQ San Carlos, US

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.